Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study

[1]  S. Yarman,et al.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas , 2018, Pituitary.

[2]  James J. Evans,et al.  Clinical Outcomes After Endoscopic Endonasal Resection of Giant Pituitary Adenomas. , 2018, World neurosurgery.

[3]  J. Eloy,et al.  Relaxing Sphenoidal Slit Incision to Extend the Anterior and Posterior Reach of Pedicled Nasoseptal Flaps During Endoscopic Skull Base Reconstruction of Transcribriform Defects: Technical Note and Results in 20 Patients. , 2018, World neurosurgery.

[4]  Ye Zhang,et al.  Expression of Matrix Metalloproteinase-9, Pituitary Tumor Transforming Gene, High Mobility Group A 2, and Ki-67 in Adrenocorticotropic Hormone-Secreting Pituitary Tumors and Their Association with Tumor Recurrence. , 2018, World neurosurgery.

[5]  I. Hochberg,et al.  Management of cystic prolactinomas: a review , 2018, Pituitary.

[6]  S. Yin,et al.  Clinically aggressive phenotype: A clinicopathological case series of atypical pituitary adenomas , 2018, Clinical Neurology and Neurosurgery.

[7]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. , 2018, European journal of endocrinology.

[8]  Odelia Cooper,et al.  Silent corticotroph adenomas , 2018, Pituitary.

[9]  C. Yedinak,et al.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review , 2018, Pituitary.

[10]  M. Lopes,et al.  The 2017 World Health Organization classification of tumors of the pituitary gland: a summary , 2017, Acta Neuropathologica.

[11]  I. Shimon.  Giant prolactinomas: Multi-modal approach to achieve tumor control , 2017, Endocrine.

[12]  M. Murad,et al.  Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[13]  A. Klibanski,et al.  Dopamine Agonists Can Reduce Cystic Prolactinomas. , 2016, The Journal of clinical endocrinology and metabolism.

[14]  A. Tirosh,et al.  Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas , 2016, Pituitary.

[15]  A. Tirosh,et al.  SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[16]  A. Tirosh,et al.  Management of macroprolactinomas , 2015, Clinical Diabetes and Endocrinology.

[17]  A. Wierinckx,et al.  Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. , 2015, European journal of endocrinology.

[18]  L. Tshibanda,et al.  Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference , 2015, Neuroradiology.

[19]  E. Laws,et al.  Current indications for the surgical treatment of prolactinomas , 2015, Journal of Clinical Neuroscience.

[20]  P. Chanson,et al.  Pituitary Apoplexy. , 2015, Endocrine reviews.

[21]  Odelia Cooper.  Silent corticotroph adenomas , 2015, Pituitary.

[22]  A. Tirosh,et al.  Hypopituitarism patterns and prevalence among men with macroprolactinomas , 2015, Pituitary.

[23]  E. Laws,et al.  Descriptive epidemiology of pituitary tumors in the United States, 2004-2009. , 2014, Journal of neurosurgery.

[24]  C. Benbassat,et al.  Women with prolactinomas presented at the postmenopausal period , 2014, Endocrine.

[25]  M. Molitch.  Management of medically refractory prolactinoma , 2014, Journal of Neuro-Oncology.

[26]  C. Villabona,et al.  Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome , 2012, Clinical endocrinology.

[27]  C. Mercieca,et al.  Prevalence and incidence of pituitary adenomas: a population based study in Malta , 2012, Pituitary.

[28]  C. Li,et al.  Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender , 2012, Journal of Endocrinological Investigation.

[29]  Manish K Aghi,et al.  Dopamine agonist-resistant prolactinomas. , 2011, Journal of neurosurgery.

[30]  Q. Pang,et al.  Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. , 2011, European journal of endocrinology.

[31]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[32]  S. Gui,et al.  Effects of estrogen receptor antagonist on biological behavior and expression of growth factors in the prolactinoma MMQ cell line , 2011, Journal of Neuro-Oncology.

[33]  R. Wallace,et al.  Demographic differences in incidence for pituitary adenoma , 2011, Pituitary.

[34]  I. Vajtai,et al.  Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists , 2010, Pituitary.

[35]  A. Klibanski,et al.  Clinical practice. Prolactinomas. , 2010, The New England journal of medicine.

[36]  Alberto Fernández,et al.  Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.

[37]  Steven D Chang,et al.  Non-surgical management of hormone-secreting pituitary tumors , 2009, Journal of Clinical Neuroscience.

[38]  P. Souverein,et al.  Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. , 2009, The Journal of clinical endocrinology and metabolism.

[39]  J. Romijn,et al.  Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. , 2009, European journal of internal medicine.

[40]  T. Hori,et al.  Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. , 2008, The Journal of clinical endocrinology and metabolism.

[41]  C. Nimsky,et al.  Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. , 2008, European journal of endocrinology.

[42]  Charles B. Wilson,et al.  Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection , 2008, Pituitary.

[43]  M. Vaněčková,et al.  Macroprolactinomas: retrospective follow up study in the MR imaging and correlation with clinical symptomatology. , 2007, Neuro endocrinology letters.

[44]  C. Benbassat,et al.  Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. , 2007, European journal of endocrinology.

[45]  D. Giannella‐Neto,et al.  PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes , 2007, Molecular Cancer.

[46]  A. Beckers,et al.  High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.

[47]  J. Schlechte,et al.  Management of resistant prolactinomas , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[48]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[49]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[50]  A. Beckers,et al.  The Epidemiology of Prolactinomas , 2017, Pituitary.

[51]  H. Koh,et al.  Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma , 2005, Journal of Korean medical science.

[52]  G. Sassolas,et al.  Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance , 2005, Acta Neurochirurgica.

[53]  Shereen Ezzat,et al.  The prevalence of pituitary adenomas , 2004, Cancer.

[54]  W. Couldwell,et al.  Contemporary management of prolactinomas. , 2004, Neurosurgical focus.

[55]  P. Cappabianca,et al.  Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. , 2003, European journal of endocrinology.

[56]  M. Losa,et al.  Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. , 2002, The Journal of clinical endocrinology and metabolism.

[57]  H. Nishioka,et al.  Gender-related differences in prolactin secretion in pituitary prolactinomas , 2002, Neuroradiology.

[58]  D. Pauler,et al.  Primary medical therapy of micro- and macroprolactinomas in men. , 2000, The Journal of clinical endocrinology and metabolism.

[59]  T. Ozgen,et al.  Prolactin Secreting Pituitary Adenomas: Analysis of 429 Surgically Treated Patients, Effect of Adjuvant Treatment Modalities and Review of the Literature , 1999, Acta Neurochirurgica.

[60]  J. Donckier,et al.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.

[61]  I. Shimon,et al.  Prolactinoma in 53 men: Clinical characteristics and modes of treatment (male prolactinoma) , 1995, Journal of endocrinological investigation.

[62]  G. Teasdale,et al.  Ten year follow up of microprolactinoma treated by transsphenoidal surgery , 1994, BMJ.

[63]  R. Fahlbusch,et al.  INFLUENCE OF PREOPERATIVE BROMOCRIPTINE THERAPY ON SUCCESS OF SURGERY FOR MICROPROLACTINOMA , 1984, The Lancet.

[64]  R. Danis.  THE TREATMENT OF FRACTURES , 1924, Lancet.